Expand all sections

Sunitinib

Sutent

Extended indication Adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following
Therapeutic value No judgement
Total cost 312,727.50

Product

Active substance Sunitinib
Domain Oncology and Hematology
Main indication Kidney cancer
Extended indication Adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.
Proprietary name Sutent
Manufacturer Pfizer
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date July 2018
Expected Registration March 2018
Orphan drug No
Additional remarks Dit is een indicatie-uitbreiding.

Therapeutic value

Therapeutic value No judgement

Expected patient volume per year

Patient volume

5 - 10

Market share is generally not included unless otherwise stated.
References Fabrikant; NKR; Chin et al. Rev Urol. 2006 Winter;8(1):1-7
Additional remarks Fabrikant: Op basis van de richtlijnen en het te verwachten CieBOM advies zal het om een zeer gelimiteerd aantal hoogrisico patiënten per jaar (5-10) gaan. NKR: 2316 patienten met niercarcinomen in 2015. Terugkeren niercarcinoom na nefrectomie is 20-40%.

Expected cost per patient per year

Cost < 41,697.00
References Fabrikant
Additional remarks Taxeprijs Sutent 50mg is €4632,98. Uitgaande van maximale behandeling van 9 cycli met maximale dosering (50mg) per jaar.

Potential total cost per year

Total cost

312,727.50

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.